Core Insights - Edwards Lifesciences announced successful patient outcomes for its mitral and tricuspid therapies, with one-year data from the ENCIRCLE trial meeting all primary and secondary endpoints for safety and effectiveness [1] - The outcomes were published in The Lancet, highlighting the significance of the findings in the medical community [1] - Additionally, thirty-day data from the EVOQUE system STS/ACC TVT Registry was reported, which is noted as the largest real-world transcatheter tricuspid valve replacement registry [1]